Azitra Consensus Price Target Decreased by 13.55% to $0.68
The average one-year price target for Azitra (NYSEAM:AZTR) has been revised to $0.68 / share on October 2, 2026, a decrease of 13.55% from the prior estimate of $0.79 dated September 11, 2026. These figures represent aggregate analyst targets compiled by Fintel and do not constitute a recommendation orinvestment adviceby Fintel.
The latest targets range from a low of $0.34 to a high of $1.05 / share. The average price target represents an increase of 431.83% from the latest reported closing price of $0.13 / share, recorded on October 1, 2026.
The mean target was $0.79 on August 5, 2026, August 28, 2026, and September 16, 2026 before adjusting to $0.68 on October 2, 2026. The latest $0.68 is the observed twelve-month low mean; the observed twelve-month high mean was $12.23 on November 17, 2025. The target change since the 90-day baseline date of June 30, 2026, is -13.55%.
The stock closed at $0.13 on October 1, 2026, a one-week price change of -23.05% from $0.17 on September 24, 2026, and a one-month price change of -27.28% from $0.18 on September 1, 2026.
In its latest earnings report on August 12, 2026, the company reported an actual EPS of -0.17, compared to an estimated EPS of -0.1173; both actual and estimated revenue for the period were reported as $0.00.
Analyst recommendations as of September 1, 2026: 2 strong buy, 4 buy, and 1 hold (7 total).
Azitra is classified under the Trading Companies & Distributors GICS sub-industry. Within this sub-industry, 33 companies are covered, with 12 experiencing raised targets, 4 lowered, and 17 remaining unchanged. The sub-industry median revision percent is 0.00%, and the median implied change percent is +40.05%.
| Company Name | Target revision | Implied change |
|---|---|---|
| Arcutis Biotherapeutics | +0.34% | +49.23% |
| Seres Therapeutics | 0.00% | +491.81% |
| Krystal Biotech | 0.00% | +14.23% |
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.